YouTube video by Ishome - Topic

First randomized study to evaluate TAVR versus clinical surveillance in moderate AS

EARLY TAVR: Economic Analysis Supports TAVI Over Clinical Surveillance for Asymptomatic AS mosbey@crf.org Sun, 11/01/2026 - 20:13 Bailey Salimes Immediate costs are higher for TAVI, but patients and the healthcare system benefit long-term from earlier intervention.

Bought Edwards Lifesciences stock Feb 6 – Jul 24, 2024? A $39M settlement pays an estimated $0.66 a share before fees. Claims due Dec 2, 2026.

Transcatheter aortic valve replacement (TAVR) has expanded across surgical-risk categories; utilization among younger patients remains insufficiently characterized. We evaluated temporal trends in TAV...

For patients with moderate aortic stenosis, current guidelines recommend clinical surveillance with echocardiographic assessment every 1 or 2 years. Whether transcatheter aortic-valve replacement (...

Self-expanding valves, a history of stroke, renal dysfunction and nontransfemoral access were all linked to an increased risk of in-hospital stroke after TAVR. “Despite advances in valve design and te...

The Evolut Low Risk Trial mosbey@crf.org Wed, 11/04/2026 - 07:57 3 hours 23 minutes ago Michael J. Reardon and C. Michael Gibson discuss the 5-year outcomes of TAVR or SAVR in low-risk patients with AS.

Patients with moderate aortic stenosis, a narrowing of the heart's aortic valve, may benefit from undergoing transcatheter aortic valve replacement (TAVR) before the disease becomes severe, according to findings from a clinical trial co-led by Cedars-Sinai investigators.

Patients with moderate aortic stenosis, a narrowing of the heart's aortic valve, may benefit from undergoing transcatheter aortic valve replacement (TAVR) before the disease becomes severe, according to findings from a clinical trial co-led by Cedars-Sinai investigators.

New research simultaneously published in the Journal of the Society for Cardiovascular Angiography & Interventions and presented at TCT 2026 found that the annual number of transcatheter aortic valve replacement (TAVR) procedures among patients younger than 70 increased nearly ninefold within one health system, rising from 15 in 2014 to 134 in 2024. Surgical aortic valve replacement (SAVR) remained the predominant approach across the age groups studied.

IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended September 30, 2026. Q3 Financial Highlights Q3 sales grew 10.5% to $1.72 billion1, constant currency2 sales grew 11.2% Q3 TAVR sales grew 8.0% to $1.24 billion1, constant currency2 sales grew 8.8% Q3 TMTT sales grew 44.0% to $207 million1,3, constant currency2 sales grew 45.6%3 Q3 EPS of $0.531; adjusted2 EPS of $0.801 which grew 19% versus prior year 2026 Outlook Increasing total company sales2 growth guidance to approximately 11.5% from 10% to 11% Increasing TAVR sales2 growth guidance to 9.0% to 9.5% from 8% to 9% Increasing TMTT sales guidance to $780 to $790 million from $760 to $780 million Increasing adjusted EPS guidance to $2.97 to $3.05 from $2.95 to $3.05, growing 18% at midpoint versus prior year 2026 performance and milestone achievements reinforce long-term durable growth Recent Highlights PROGRESS trial marks turning point in the management of moderate AS Practice-changing data adding to Edwards’ body of structural heart clinical evidence presented at TCT Final TAVR NCD represents important step toward expanding access to timely, high-quality care U.S. approval of PASCAL Precision for tricuspid repair expands access to differentiated therapy U.S. approval of PASCAL Ace...